{
    "id": 4051,
    "name": "alveolar rhabdomyosarcoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "4382"
    ],
    "termId": "DOID:4051",
    "evidence": [
        {
            "id": 2060,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 resulted in antitumor activity in an alveolar rhabdomyosarcoma patient derived xenograft model (PMID: 24687871).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2537,
                    "pubMedId": 24687871,
                    "title": "Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24687871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10014,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DIM-C-pPhCO2Me treatment in an alveolar rhabdomyosarcoma cell line resulted in decreased cell migration in culture and decreased PAX3-FOXO1 expression and reduced metastasis in xenograft models (PMID: 27864345).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 5345,
                "therapyName": "DIM-C-pPhCO2Me",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7908,
                    "pubMedId": 27864345,
                    "title": "PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27864345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK525762 inhibited growth of alveolar rhabdomyosarcoma cell lines harboring PAX3-FOXO1 in culture (PMID: 28446439).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9685,
                    "pubMedId": 28446439,
                    "title": "PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11649,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 reduced PAX3-FOXO1 directed transcriptional activity and inhibited growth of alveolar rhabdomyosarcoma (RMS) cell lines harboring PAX3-FOXO1 in culture, and inhibited tumor growth in PAX3-FOXO1-positive alveolar RMS cell line and patient-derived xenograft (PDX) models (PMID: 28446439).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9685,
                    "pubMedId": 28446439,
                    "title": "PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Birabresib (OTX015) inhibited growth of alveolar rhabdomyosarcoma cell lines harboring PAX3-FOXO1 in culture (PMID: 28446439).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9685,
                    "pubMedId": 28446439,
                    "title": "PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20032,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "PAX3-FOXO1 fusions aid the diagnosis of alveolar rhabdomyosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20033,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "PAX3-FOXO1 fusions aid the diagnosis of alveolar rhabdomyosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 33065,
                "profileName": "PAX7 - FOXO1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02567435",
            "title": "Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1435,
                    "therapyName": "Cyclophosphamide + Dactinomycin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02748135",
            "title": "A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 4704,
                    "therapyName": "TB-403",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02978859",
            "title": "MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1655,
                    "therapyName": "MGCD516",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03041701",
            "title": "Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5287,
                    "therapyName": "Dasatinib + Ganitumab",
                    "synonyms": null
                }
            ]
        }
    ]
}